3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
4
Sarcoma
2
Lymphoid
2
Head & Neck
2
Genitourinary
2
Endocrine
2
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Wilms Tumor
1
Thrombocytosis
1
Sarcoma, Ewing
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Interventions
Radiosurgery
9
Magnetic Resonance Spectroscopy
6
pembrolizumab
4
Radiotherapy
4
Nivolumab
4
Fluorodeoxyglucose F18
4
cabozantinib
3
Specimen Handling
3
Paclitaxel
3
Melphalan
3
Ipilimumab
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Busulfan
3
lenvatinib
2
entrectinib
2
cediranib
2
Thiotepa
2
Sunitinib
2
Radiation
2
Peripheral Blood Stem Cell Transplantation
2
Injections
2
Ifosfamide
2
FAPI-46
2
Etoposide
2
Carboplatin
2
Bone Marrow Transplantation
2
Bevacizumab
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
trioctyl phosphine oxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
entrectinib
×
Genitourinary
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA